Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
We know these are worrying times. We have gathered information to answer your questions and concerns.
Join the webinar on Scleroderma and COVID-19 this Saturday, March 21.
Read about positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ofev.